Datasite Acquires Leading Private Market Intelligence Company Grata with $500 Million Investment Commitment
Datasite, the global SaaS provider of AI-powered workflow collaboration and automation solutions for M&A, investment and strategic projects, today announced that it has acquired Grata, a leading AI-native, private market intelligence company. CapVest Partners LLP ('CapVest'), the controlling shareholder of Datasite, intends to invest $500 million, organically and inorganically, to further expand Datasite's intelligence solutions.
Advertisement
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603748893/en/
'This landmark combination creates a unique market intelligence offering for enterprises globally,' said Rusty Wiley, CEO and President of Datasite. 'Grata has comprehensive, accurate and searchable data on private companies. Combine that with the Datasite Group's anonymized and aggregated insights – from the largest and most trusted database in the world, capturing over 55,000 projects every year – and you've got an unmatched powerhouse of market intelligence.'
Founded in 2016, New York-based Grata offers an AI-native platform for private market workflows combining proprietary company data with integrated dealmaking software solutions. Datasite's acquisition and ongoing investment in Grata will accelerate the growth of its pioneering, deal sourcing and market intelligence tools. Co-founders Andrew Bocskocsky and Nevin Raj will continue to lead Grata as a strategic business unit within Datasite.
'We are thrilled to join the Datasite team and back our shared vision with significant investment,' said Andrew Bocskocsky, CEO and Co-Founder of Grata. 'Together, with Datasite's global footprint, we are expanding our reach to international markets and creating unprecedented value for users.'
Christopher Campbell, Partner at CapVest, said, 'Obtaining accurate, real-time data on private markets will further enable enterprises and investors to execute their strategic priorities. We welcome Grata to the Datasite Group and look forward to bringing unique insights to the M&A community.'
Datasite was advised by Arma Partners (M&A), Willkie Farr & Gallagher LLP (Legal), Alvarez & Marsal (Financial), KPMG (Tax), Lockton (Insurance) and West Monroe (Technology). Grata was advised by Deutsche Bank (M&A) and Orrick (Legal).
To learn more about Datasite, please visit: www.datasite.com.
About Datasite
Datasite is a global SaaS provider of AI-powered workflow collaboration and automation solutions for M&A, investment and strategic projects. Datasite's innovative products drive execution, while generating unique data insights to empower knowledge workers around the world to succeed across the entire project lifecycle.
For more information, visit www.datasite.com
About Grata
Grata is a leading AI-native private market intelligence and dealmaking company. Grata has the most comprehensive, accurate, and searchable data on private companies.
For more information, visit www.grata.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250603748893/en/
Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
15 minutes ago
- Wall Street Journal
Today's High-Yield Savings Rates for July 31, 2025
Getting the best rate as a saver has been a little more difficult since the Federal Reserve started cutting its benchmark rate toward the end of 2024. Since the beginning of 2025, Fed officials have adopted a wait-and-see approach due to concerns about tariffs and economic conditions. The central bank again held the federal-funds rate steady in July as officials weighed how higher duties on imports will affect retailers and consumers. With the average savings account paying 0.38%, according to the Federal Deposit Insurance Corporation (FDIC), it might feel a little bleak for savers. However, high-yield savings accounts still offer a way to get a little more yield. The best high-yield savings account pays a much higher yield. Indeed, the top rate from a national bank is 4.66% APY, according to Locally, you might be able to check with a credit union or community bank. For example, ConnectOne Bank in New York offers an APY of 4.00% if you have at least $2,500 deposited.
Yahoo
20 minutes ago
- Yahoo
Why Eli Lilly Stock Was Looking Sickly Today
Key Points Investors were spooked by a peer's notable reduction in sales and profitability guidance. This peer was Novo Nordisk, which like Eli Lilly sells a popular drug approved specifically for obesity. 10 stocks we like better than Eli Lilly › One of the more popular stocks in the pharmaceutical sector of late got the cold shoulder from investors on Tuesday. Eli Lilly (NYSE: LLY) closed today's trading session down by almost 6% in value, which was notably worse than the 0.3% drop of the bellwether S&P 500 index. That decline wasn't necessarily Eli Lilly's fault, though. Reducing weight, reducing guidance Eli Lilly's recent popularity is due in no small measure to its plunge into the highly lucrative weight-loss drug market. In late 2023, its Zepbound -- essentially the same treatment as its diabetes drug Mounjaro -- was approved to treat obesity, and the company was off to the races. On Tuesday, though, the standard-bearer for the segment took quite a tumble. That was Novo Nordisk, which this morning lowered its guidance for both full-year sales and operating profit. The growth forecast for the former was reduced to 8% to 14% over the 2024 tally (previous guidance range: 13% to 21%). Ditto for operating profit, which is now expected to rise in a range of 10% to 16%. That would be encouraging, if it weren't for the fact that management's preceding prediction was 16% to 24%. Novo Nordisk is known for developing and selling Wegovy, the first GLP-1 drug approved by the U.S. Food and Drug Administration specifically for weight loss. The company has flown to renown and admiration on the wings of that drug, which remains a key product. Investors probably fear that Eli Lilly's Zepbound will also perform worse than expected. Not an emergency I don't think anyone should push the panic button on Eli Lilly due to this (or Novo Nordisk, while I'm at it). Demand for obesity drugs remains strong and nearly unlimited, so both Zepbound and Wegovy -- which still benefit from a lack of competitors, at least for now -- should continue to be growth drivers. Also, in the case of Eli Lilly, the sprawling pharmaceutical company has a vast portfolio and a very wide development pipeline, so it's hardly dependent on one drug -- no matter how currently popular that drug might be. Should you buy stock in Eli Lilly right now? Before you buy stock in Eli Lilly, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Eli Lilly wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $633,452!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,083,392!* Now, it's worth noting Stock Advisor's total average return is 1,046% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Why Eli Lilly Stock Was Looking Sickly Today was originally published by The Motley Fool
Yahoo
40 minutes ago
- Yahoo
What Are Wall Street Analysts' Target Price for Citigroup Stock?
Valued at a market cap of $176.5 billion, Citigroup Inc. (C) operates as one of the largest financial institutions in the world. The New York-based financial giant focuses on safeguarding assets, lending money, making payments, and accessing the capital markets on behalf of its clients. Its customers include corporations, governments, institutions, as well as individuals. The financial giant has notably outpaced the broader market over the past year. C stock has soared 36.1% on a YTD basis and 45.5% over the past 52 weeks, outperforming the S&P 500 Index's ($SPX) 8.2% surge in 2025 and 17% gains over the past year. More News from Barchart Morgan Stanley Says Nvidia Has 'Exceptional' Strength. Should You Buy NVDA Stock Here? This Dividend Stock Yields 4.5% But Is Down 21% in 2025: Time to Buy? Dear MicroStrategy Stock Fans, Mark Your Calendars for July 31 Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. Narrowing the focus, Citi has also outperformed the Financial Select Sector SPDR Fund's (XLF) 9% gains in 2025 and 20.2% returns over the past 52 weeks. Citigroup's stock prices gained 3.7% following the release of its impressive Q2 results on Jul. 15. The company showcased its resilience by delivering a solid 8.2% year-over-year growth in total revenues to $21.7 billion despite the macro uncertainties. This figure also surpassed the Street expectations by 4.4%. Furthermore, driven by higher net income and share repurchases, its EPS for the quarter came in at $1.96, up 28.9% year-over-year and 21.7% above the consensus estimate. For the full fiscal 2025, ending in December, analysts expect Citigroup to deliver an EPS of $7.59, up 27.6% year-over-year. Furthermore, the company has a solid earnings surprise history. It has surpassed the Street's bottom-line estimates in each of the past four quarters. Citi stock maintains a consensus 'Moderate Buy' rating overall. Of the 23 analysts covering the stock, opinions include 12 'Strong Buys,' five 'Moderate Buys,' and six 'Holds.' This configuration is marginally more bullish than a month ago, when only four analysts gave 'Moderate Buy' recommendations. On Jul. 30, Oppenheimer analyst Chris Kotowski reiterated an 'Outperform' rating on the stock, while raising the price target to $124. Citigroup's mean price target of $100.85 represents a modest 5.3% premium to current price levels. On the date of publication, Aditya Sarawgi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Sign in to access your portfolio
